LAPEX BCS
510(k) K081962
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK081962 | Date29 Dec 2008 | StatusActive |
Recalls
No FDA recalls found in the data synced 22 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- ILY
- Device Class
- Class II
- Regulation
- 21 CFR Part 890.5500
- Advisory Committee
- Physical Medicine
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 23 Sep 2026
The LAPEX BCS is a device classified under the product code ILY, which corresponds to a physical medicine device. It was determined to be substantially equivalent to a predicate device through a traditional 510(k) clearance process.
The device was manufactured by Meridian Co., Ltd. and received FDA 510(k) clearance under K081962 on December 29, 2008. It is authorized for distribution in the United States and is identified by the applicant and manufacturer as Meridian Co., Ltd. with an address in Deer Field, IL.
Other devices from Meridian AG
Questions
AI-generated answers, 23 Sep 2026
What is the LAPEX BCS device used for?
The LAPEX BCS is classified under product code ILY, which corresponds to a physical medicine device, indicating its use in physical medicine applications as determined by its FDA 510(k) clearance.
Who manufactures the LAPEX BCS and where are they located?
The LAPEX BCS is manufactured by Meridian Co., Ltd., with their address listed as P.O. Box 7007, Deer Field, IL 60015, United States, as recorded in the FDA 510(k) submission.
What regulatory pathway was used for the LAPEX BCS clearance?
The LAPEX BCS received FDA 510(k) clearance through a traditional 510(k) process, determined to be substantially equivalent to a predicate device under decision code SESE.
When was the LAPEX BCS cleared by the FDA and under what k-number?
The LAPEX BCS was cleared by the FDA on December 29, 2008, under k-number K081962, following submission on July 9, 2008, and is authorized for distribution in the United States.